GODAVARI
Godavari Drugs financials
- Market cap
- ₹130 Cr
Quarterly results
Q1 FY27: revenue up 17.4%, net profit up 6.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26 | 30 | 26 | 24 | 27 +2% | 22 −25% | 33 +30% | 28 +17% |
| EBITDA | 3 | 3 | 3 | 3 | 2 −31% | 2 −4% | 3 −5% | 3 −13% |
| Net profit | 1 | 1 | 1 | 1 | 1 −8% | 1 −1% | 1 +45% | 1 +7% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +42.4% 1Y
1Y: ₹83.59 on 10 Sept 2025 → ₹119. High ₹130.15 (8 May 2026), low ₹70.24 (9 Dec 2025).
Financials, as filed
Revenue fell 17.8% a year over 2 years, FY24 to FY26. Operating margin widened to 9.7%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹157 Cr | ₹113 Cr | ₹106 Cr |
| Operating profit | ₹13 Cr | ₹12 Cr | ₹10 Cr |
| Operating margin | 8.5% | 10.4% | 9.7% |
| Interest | ₹5 Cr | ₹5 Cr | ₹4 Cr |
| Depreciation | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Net profit | ₹6 Cr | ₹4 Cr | ₹4 Cr |
| Net margin | 3.5% | 3.9% | 3.9% |
| Cash from operations | ₹18 Cr | ₹11 Cr | ₹1 Cr |
| Free cash flow | ₹5 Cr | ₹-9 Cr | ₹-26 Cr |
| ROCE | 14.0% | 10.0% | 7.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹10 Cr |
| Reserves | ₹17 Cr | ₹22 Cr | ₹26 Cr | ₹31 Cr | ₹38 Cr | ₹66 Cr |
| Borrowings | ₹30 Cr | ₹23 Cr | ₹36 Cr | ₹58 Cr | ₹74 Cr | ₹82 Cr |
| Other liabilities | ₹36 Cr | ₹49 Cr | ₹52 Cr | ₹38 Cr | ₹43 Cr | ₹43 Cr |
| Total liabilities | ₹91 Cr | ₹101 Cr | ₹121 Cr | ₹135 Cr | ₹162 Cr | ₹200 Cr |
| Fixed assets | ₹22 Cr | ₹26 Cr | ₹25 Cr | ₹27 Cr | ₹31 Cr | ₹30 Cr |
| Capital work in progress | ₹1 Cr | ₹0 Cr | ₹9 Cr | ₹18 Cr | ₹41 Cr | ₹57 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹68 Cr | ₹75 Cr | ₹87 Cr | ₹90 Cr | ₹90 Cr | ₹114 Cr |
| Total assets | ₹91 Cr | ₹101 Cr | ₹121 Cr | ₹135 Cr | ₹162 Cr | ₹200 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −12.40 pp while the public added +10.17 pp. The shareholder count shrank 14% to 6,722.
- Promoters
- 40.2%
- DIIs
- 2.7%
- Public
- 57.0%
Since Jun 2025
- Promoters −12.40 pp
- Public +10.17 pp
- DIIs +2.24 pp
How it drifted, 12 quarters
Over this window promoters fell from 53.2% to 40.2% — −12.9 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 53.2%, DIIs 0.5%, Public 46.3%.Dec '23: Promoters 53.2%, DIIs 0.5%, Public 46.4%.Mar '24: Promoters 53.2%, DIIs 0.5%, Public 46.3%.Jun '24: Promoters 53.2%, DIIs 0.5%, Public 46.3%.Sep '24: Promoters 52.6%, DIIs 0.5%, Public 46.9%.Dec '24: Promoters 52.6%, DIIs 0.5%, Public 46.9%.Mar '25: Promoters 52.6%, DIIs 0.5%, Public 46.9%.Jun '25: Promoters 52.6%, DIIs 0.5%, Public 46.9%.Sep '25: Promoters 52.6%, DIIs 0.5%, Public 46.9%.Dec '25: Promoters 52.6%, DIIs 0.5%, Public 46.9%.Mar '26: Promoters 40.2%, DIIs 2.5%, Public 57.3%.Jun '26: Promoters 40.2%, DIIs 2.7%, Public 57.0%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Moneybee Investment Trust - Flyingbee Investment Fund AIF newly disclosed 1.26% held
The same filing shows 0 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Godavari Drugs Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Sushma Kakani | 11.40% | unchanged |
| Kamala Jaju | 8.99% | unchanged |
| Mohit Jaju | 5.28% | unchanged |
| Ghanshyam Jaju | 3.46% | unchanged |
| Mukund Kakani | 3.46% | unchanged |
| Aksheit Kakani | 3.22% | unchanged |
| Suryatej Advisors Llp | 2.22% | unchanged |
| Sachin Kasera | 2.22% | unchanged |
| Highcrestt Global Company Ltd | 1.97% | unchanged |
| Priyanka Jaju | 1.83% | unchanged |
| Ketan V Thakkar | 1.66% | unchanged |
| Umesh Kumar Gupta | 1.40% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Godavari Drugs Ltd.
Guides on how to read this kind of business and the numbers that matter.